We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-19.38%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$264M
AUM Growth
-$174M
(-40%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-39.14%
Top 10 Holdings %
Top 10 Hldgs %
67.94%
Holding
42
New
13
Increased
4
Reduced
13
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$21.5M |
| 2 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$12.2M |
| 3 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$9.79M |
| 4 |
Viatris
VTRS
|
+$8.62M |
| 5 |
Quest Diagnostics
DGX
|
+$7.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bio-Rad Laboratories Class A
BIO
|
+$22.1M |
| 2 |
Zimmer Biomet
ZBH
|
+$18.6M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
+$18.6M |
| 4 |
Johnson & Johnson
JNJ
|
+$18M |
| 5 |
Medtronic
MDT
|
+$17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.22% |
| 2 | Technology | 6.62% |
| 3 | Financials | 0.53% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
ICU Medical
ICUI
$4.21B
| $2.22M | 0.84% |
11,000
-59,000
| -84% | -$11.4M |
|
27
Edwards Lifesciences
EW
$49.6B
| $1.89M | 0.71% |
+30,000
| New | +$2.16M |
|
|
MSON
28
DELISTED
Misonix Inc
MSON
| $1.87M | 0.71% |
+198,800
| New | +$3.02M |
|
29
eHealth
EHTH
$42.2M
| $1.41M | 0.53% |
+10,000
| New | +$1.15M |
|
30
Insulet
PODD
$11.5B
| $828K | 0.31% |
+5,000
| New | +$914K |
|
31
Integer Holdings
ITGR
$4.12B
| $629K | 0.24% |
10,000
-155,000
| -94% | -$12.6M |
|
32
CALL
Charles River Laboratories
CRL
$11.2B
| – | – |
-218
| Closed | -$279K |
|
33
CALL
Haemonetics
HAE
$3.89B
| – | – |
-500
| Closed | -$24K |
|
34
Inogen
INGN
$175M
| – | – |
-75,000
| Closed | -$4.98M |
|
|
35
CALL
Johnson & Johnson
JNJ
$618B
| – | – |
-250
| Closed | -$125K |
|
|
36
Johnson & Johnson
JNJ
$618B
| – | – |
-125,000
| Closed | -$18M |
|
37
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| – | – |
-8,000
| Closed | -$512K |
|
|
38
Zimmer Biomet
ZBH
$18.2B
| – | – |
-128,750
| Closed | -$18.6M |
|
|
NVRO
39
DELISTED
NEVRO CORP.
NVRO
| – | – |
-40,000
| Closed | -$4.72M |
|
|
SRCL
40
DELISTED
Stericycle Inc
SRCL
| – | – |
-300,000
| Closed | -$18.6M |
|
|
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-595,000
| Closed | -$14.3M |
|
|
CORV
42
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| – | – |
-2,500,000
| Closed | -$1.02M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q1 2020 Portfolio in Review
As of Q1 2020, Tamarack Advisers held 42 positions worth $264M, down 40% from $438M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers withdrew a net $103M in Q1 2020, closing 11 positions and reducing 13 holdings. Its most notable exit was Zimmer Biomet, an estimated $18.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Technology and Financials.
Against the trend, Tamarack Advisers opened a new position in Perrigo worth $19.2M.
- Tamarack Advisers's largest Q1 2020 buy was Perrigo: 400,000 shares worth $19.2M.
- Tamarack Advisers added most to Viatris in Q1 2020, an estimated $8.62M increase.
- Tamarack Advisers's biggest Q1 2020 reduction was Bio-Rad Laboratories Class A, cutting an estimated $22.1M.
- Tamarack Advisers fully exited Zimmer Biomet in Q1 2020, selling an estimated $18.6M.
- Tamarack Advisers's ten largest holdings make up 68% of its $264M portfolio in Q1 2020.
- Tamarack Advisers opened 13 new positions and closed 11 in Q1 2020.
- Tamarack Advisers's portfolio value fell 40% quarter-over-quarter to $264M.
Based on Tamarack Advisers's 13F filing for Q1 2020, filed 14 May 2020.